A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Conditional survival (CS) provides important information on survival for a period of time after diagnosis. Currently, information on CS patterns of patients with nasopharyngeal carcinoma (NPC) is lacking. We aimed to analyze survival rate over time and estimate CS for NPC patients using a national population-based registry. Materials and Methods Patients diagnosed with NPC between 1973 and 2007 with at least 5-year follow-up were identified from the Surveillance Epidemiology End Results registry. Traditional survival rates and crude CS estimates were calculated using Kaplan-Meier analysis. Risk-adjusted survival curves were plotted from the proportional hazards model using the correct group prognosis method. Results For 7,713 patients analyzed, adjusted baseline 5-year overall survival improved significantly from 36.0% in patients diagnosed in 1973-1979, 41.7% in 1980-1989, 46.6% in 1990- 1999, to 54.7% in 2000-2007 (p < 0.01). CS analysis demonstrated that for every additional year survived, adjusted probability of surviving the next 5 years increased from 66.7% (localized), 54.0% (regional), and 35.3% (distant) at the time of diagnosis, to 83.7% (localized), 75.0% (regional), and 62.2% (distant) for patients who had survived 5 years. Adjusted 5-year CS differed among age, sex, tumor histology, ethnicity, and stage subgroups initially, but converged with time. Conclusion Treatment outcomes of NPC patients have greatly improved over the decades. Increases in CS become more prominent in patients with distant disease than in those with localized or regional disease as patients survive longer. CS provides more dynamic prognostic information for patients who have survived a period of time after diagnosis.
Abstract
Purpose Conditional survival (CS) provides important information on survival for a period of time after diagnosis. Currently, information on CS patterns of patients with nasopharyngeal carcinoma (NPC) is lacking. We aimed to analyze survival rate over time and estimate CS for NPC patients using a national population-based registry. Materials and Methods Patients diagnosed with NPC between 1973 and 2007 with at least 5-year follow-up were identified from the Surveillance Epidemiology End Results registry. Traditional survival rates and crude CS estimates were calculated using Kaplan-Meier analysis. Risk-adjusted survival curves were plotted from the proportional hazards model using the correct group prognosis method. Results For 7,713 patients analyzed, adjusted baseline 5-year overall survival improved significantly from 36.0% in patients diagnosed in 1973-1979, 41.7% in 1980-1989, 46.6% in 1990- 1999, to 54.7% in 2000-2007 (p < 0.01). CS analysis demonstrated that for every additional year survived, adjusted probability of surviving the next 5 years increased from 66.7% (localized), 54.0% (regional), and 35.3% (distant) at the time of diagnosis, to 83.7% (localized), 75.0% (regional), and 62.2% (distant) for patients who had survived 5 years. Adjusted 5-year CS differed among age, sex, tumor histology, ethnicity, and stage subgroups initially, but converged with time. Conclusion Treatment outcomes of NPC patients have greatly improved over the decades. Increases in CS become more prominent in patients with distant disease than in those with localized or regional disease as patients survive longer. CS provides more dynamic prognostic information for patients who have survived a period of time after diagnosis.
참고문헌 (33)
- Tang LL, "Global trends in incidence and mortality of nasopharyngeal carcinoma", Cancer Lett, 374, pp.22~30 (2016)[DOI]
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)[DOI]
- Wei KR, "Nasopharyngeal carcinoma incidence and mortality in China in 2010", Chin J Cancer, 33, pp.381~387 (2014)
- Lai SZ, "How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?", Int J Radiat Oncol Biol Phys, 80, pp.661~668 (2011)[DOI]
- Blanchard P, "Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis", Lancet Oncol, 16, pp.645~655 (2015)[DOI]
- Sun Y, "Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial", Lancet Oncol, 17, pp.1509~1520 (2016)[DOI]
- Ferrell BR, "Quality of life in long-term cancer survivors", Oncol Nurs Forum, 22, pp.915~922 (1995)
- Skuladottir H, "Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark", J Clin Oncol, 21, pp.3035~3040 (2003)[DOI]
- Merrill RM, "Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon", Dis Colon Rectum, 41, pp.1097~1106 (1998)[DOI]
- Wang SJ, "Conditional survival in gastric cancer: a SEER database analysis", Gastric Cancer, 10, pp.153~158 (2007)[DOI]
- Fukui T, "Conditional survival after surgical intervention in patients with non-small cell lung cancer", Ann Thorac Surg, 101, pp.1877~1882 (2016)[DOI]
- Fuller CD, "Conditional survival in head and neck squamous cell carcinoma: results from the SEER dataset 1973-1998", Cancer, 109, pp.1331~1343 (2007)[DOI]
- [URL]
- Chua ML, "Nasopharyngeal carcinoma", Lancet, 387, pp.1012~1024 (2016)[DOI]
- Warren JL, "Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population", Med Care, 40(8 Suppl), pp.IV~ (2002)
- Fritz A, "International classification of disease for oncology, 3rd ed" (2000)
- Summary staging guide, SEER program. NIH Publication No. 81, "National Cancer Institute", National Institute of Health, 598~603 (1981)
- Nieto FJ, "Adjusting survival curves for confounders: a review and a new method", Am J Epidemiol, 143, pp.1059~1068 (1996)[DOI]
- [URL]
- Schoenfeld D, "Partial residuals for the proportional hazards regression model", Biometrika, 69, pp.239~241 (1982)[DOI]
- Gill RD, "Multistate life-tables and regression models", Math Popul Stud, 3, pp.259~276 (1992)[DOI]
- Greene FL, "AJCC cancer staging handbook: from the AJCC cancer staging manual, 6th ed" (2002), Springer
- Xing Y, "Conditional survival estimates improve over time for patients with advanced melanoma: results from a populationbased analysis", Cancer, 116, pp.2234~2241 (2010)
- Chang GJ, "Practical application of a calculator for conditional survival in colon cancer", J Clin Oncol, 27, pp.5938~5943 (2009)[DOI]
- Xiao G, "Influence of gender and age on the survival of patients with nasopharyngeal carcinoma", BMC Cancer, 13, pp.226~ (2013)[DOI]
- OuYang PY, "The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis", Br J Cancer, 112, pp.1554~1561 (2015)[DOI]
- Ou SH, "Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology", Ann Oncol, 18, pp.29~35 (2007)[DOI]
- Wang SJ, "Conditional survival in rectal cancer: a SEER database analysis", Gastrointest Cancer Res, 1, pp.84~89 (2007)
- Deleyiannis FW, "Alcoholism: independent predictor of survival in patients with head and neck cancer", J Natl Cancer Inst, 88, pp.542~549 (1996)[DOI]
- Hsu WL, "Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan", Cancer Epidemiol Biomarkers Prev, 18, pp.1218~1226 (2009)[DOI]
- Wang SJ, "Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer", J Clin Oncol, 26, pp.2112~2117 (2008)[DOI]
- Lee AW, "Management of nasopharyngeal carcinoma: current practice and future perspective", J Clin Oncol, 33, pp.3356~3364 (2015)[DOI]
- Edge SB, "The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM", Ann Surg Oncol, 17, pp.1471~1474 (2010)[DOI]